Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Licenses Sequella Technology for TB Assay Development

NEW YORK (GenomeWeb News) – Drug firm Sequella today announced the licensing of its B-Smart nucleic acid-based technology to Laboratory Corporation of America Holdings for an undisclosed amount.

Under the terms of the agreement, LabCorp will use the B-Smart system to develop a laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis. LabCorp will also commercially use the assay in the US.

Rockville, Md.-based Sequella has retained the worldwide commercialization rights to the B-Smart technology for indications excluding tuberculosis, and for geographies outside the US for tuberculosis.

LabCorp will develop its assays combining nucleic acid testing with phage-based technology "to accurately and quickly identify any resistance of M. tuberculosis clinical isolates to antitubercular antibiotics, regardless of whether the resistance genotype is known," Sequella said in a statement. The assays will be able to identify microbes and drug susceptibility in a matter of hours or days depending on the bacterial species, it added.

Sequella said the B-Smart system is the first rapid nucleic acid-based technology that can detect drug resistance without prior information about the genes or mutations that cause resistance.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.